AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03825744
Drug: Hetrombopag Olamine+Standard Therapy
RxNorm normalized name: Eltrombopag Olamine
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT01117987
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
Trial: NCT00379509
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
Trial: NCT00806754
Drug: Ciclesonide nasal spray + placebo Azelastine
RxNorm normalized name: ciclesonide Metered Dose Nasal Spray
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide nasal spray 50 mcg + Placebo Azelastine
Trial: NCT04117945
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04117945
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00352196
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12 weeks of treatment with risperidone 0.25 to 11 mg per day.
Trial: NCT00806754
Drug: Ciclesonide nasal spray + Azelastine
RxNorm normalized name: ciclesonide Metered Dose Nasal Spray
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
Trial: NCT01226693
Drug: PH-797804 material sparing tablet
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 6mg, single dose
Trial: NCT01226693
Drug: PH-797804 Phase2b/3 with sodium lauryl sulphate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, 6mg, single dose
Trial: NCT01226693
Drug: PH-797804 Phase2b/3 without sodium lauryl sulphate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, 6mg, single dose
Trial: NCT02806791
Drug: FILGRASTIM
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04030338
Drug: 18F-DCFPyL-iPSMA
RxNorm normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
Trial: NCT00447642
Drug: LX201
RxNorm normalized name: LX201
DrugBank: LX201 (DB04943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
Trial: NCT04030338
Drug: 68Ga-HBED-iPSMA
RxNorm normalized name: (68Ga)Hbed-psma
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
Trial: NCT02163694
Drug: Veliparib Placebo
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
Trial: NCT02163694
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
Trial: NCT02163694
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
Trial: NCT02163694
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
Trial: NCT00198536
Drug: Ecabet 2.83%
DrugBank: Ecabet (DB05265)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00198536
Drug: Ecabet 3.70%
DrugBank: Ecabet (DB05265)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089973
Drug: Ispinesib
RxNorm normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
Trial: NCT04506567
Drug: 225Ac-J591
RxNorm normalized name: 225Ac-HuM195
DrugBank: Lintuzumab satetraxetan AC-225 (DB15053)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cycle of fractionated dose of 225Ac-J591
Trial: NCT04506567
Drug: 225Ac-J591
RxNorm normalized name: 225Ac-HuM195
DrugBank: Lintuzumab satetraxetan AC-225 (DB15053)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 225Ac-J591 every 6 weeks x 4
Trial: NCT00562120
Drug: Allegra
RxNorm normalized name: Allegra
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
Trial: NCT00562120
Drug: Allegra-D
RxNorm normalized name: Allegra-D
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral dose of Allegra-D is dosed to subjects as an active comparator.
Trial: NCT00562120
Drug: PF-03654746
RxNorm normalized name: PF-03654746
DrugBank: PF-03654746 (DB12201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of PF-03654746 is the investigational drug being studied.
Trial: NCT01634854
Drug: Vaginal Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
Trial: NCT01634854
Drug: Intravenous Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous
Trial: NCT04975724
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
Trial: NCT00198354
Drug: gemcitabine + cisplatine
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
Trial: NCT00198354
Drug: Paclitaxel + Carboplatine
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
Trial: NCT03699254
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.
Trial: NCT03699254
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.
Trial: NCT02105701
Drug: Grazoprevir + Elbasvir
RxNorm normalized name: elbasvir / grazoprevir
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
Trial: NCT02105701
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg capsule
Trial: NCT03977441
Drug: Agomelatine or PIacebo
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Agomelatine (DB06594)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
Trial: NCT03799822
Drug: Rivaroxaban 10 MG Oral Tablet
RxNorm normalized name: rivaroxaban 10 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: replacement of warfarin by rivaroxaban
Trial: NCT01129960
Drug: Eslicarbazepine acetate (BIA 2-093)
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets will be used.
Trial: NCT00272467
Drug: Rebamipide
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals
Trial: NCT00272467
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea.
Trial: NCT00150982
Drug: Mechanism of action of alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02813382
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
Trial: NCT02813382
Drug: Prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
Trial: NCT02813382
Drug: Chloroprocaine
RxNorm normalized name: Chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
Trial: NCT00078637
Drug: E7820
RxNorm normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04646694
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
Trial: NCT01362296
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV once every 3 weeks
Trial: NCT02682134
Drug: xylocaine
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First group were given xylocaine
Trial: NCT02682134
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second group were given Dexamethasone
Trial: NCT02682134
Drug: Xylocaine and Dexamethasone
RxNorm normalized name: Xylocaine
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Third group were given both Xylocaine and Dexamethasone
Trial: NCT02452528
Drug: ARC-520
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02452528
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 or 1.0 mg/day orally
Trial: NCT02452528
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/day orally
Trial: NCT02452528
Drug: diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg orally as pretreatment antihistamine
Trial: NCT03895229
Drug: Empagliflozin 10 MG Oral Tablet [Jardiance]
RxNorm normalized name: empagliflozin 10 MG Oral Tablet [Jardiance]
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
Trial: NCT00568711
Drug: rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 5-day course of daily 600-mg doses of rifampin
Trial: NCT03277638
Drug: Pembrolizumab at 7 days prior
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab injections 7 days before surgery
Trial: NCT01244425
Drug: Fibrin Sealant (FS) VH S/D 500 s-apr
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: spray application; dosage frequency: single application
Trial: NCT03277638
Drug: Pembrolizumab at 14 days post
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab injections 14 days after surgery
Trial: NCT03277638
Drug: Pembrolizumab at 35 days post
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab injections 35 days after surgery
Trial: NCT01398839
Drug: Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both treatment and sham groups will receive riboflavin
Trial: NCT01965626
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg twice per day, 10 consecutive days
Trial: NCT01965626
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HD-DXM (orally at 40 mg daily for 4d)
Trial: NCT01465568
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60mg subcutaneous injection 6 monthly for 2 doses
Trial: NCT04351347
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivermectin
Trial: NCT01977456
Drug: Eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
Trial: NCT01598545
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
Trial: NCT00007787
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00349401
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00856622
Drug: i. Fixed combination of latanoprost 0.005% and timolol 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one drop in the morning and placebo in the evening
Trial: NCT00856622
Drug: timolol 0.5% ophthalmic solution
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one drop in the morning and evening
Trial: NCT00856622
Drug: latanoprost 0.005% ophthalmic solution
RxNorm normalized name: Latanoprost 0.005% Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: placebo in the morning and latanoprost .005% in the evening
Trial: NCT02569541
Drug: sodium fusidate
RxNorm normalized name: Sodium fusidate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02042378
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
Trial: NCT02547454
Drug: Methoxy polyethylene glycol-epoetin beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00290264
Drug: Budesonide/formoterol
RxNorm normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04433494
Drug: TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TY-302 is taken orally. Tamoxifen is taken orally.
Trial: NCT02335372
Drug: Proflavine Solution
RxNorm normalized name: proflavine
DrugBank: Proflavine (DB01123)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
Trial: NCT00697801
Drug: MAP0010 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
Trial: NCT00697801
Drug: MAP0010 high dose
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
Trial: NCT02381249
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
Trial: NCT02485158
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
Trial: NCT02485158
Drug: AMP
RxNorm normalized name: AMP
DrugBank: Adenosine phosphate (DB00131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
Trial: NCT02485158
Drug: ALC
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
Trial: NCT01347008
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sildenafil citratre, 50mg b.i.d., 8 weeks
Trial: NCT00459108
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT00030407
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
Trial: NCT02993705
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy drug
Trial: NCT00256893
Drug: ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00122447
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 325 mg PO QD